Physician profile
Paul J Smith
NPI 1871527010
$883.01
in general payments reported to CMS, 2019-2025
14 companies · $53.80 in 2025
The $53.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.74 · 2020: $151 · 2021: $180 · 2022: $169 · 2023: $181 · 2024: $71.26 · 2025: $53.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.04 | 2021-2025 | |
| Novo Nordisk INC | $142.24 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $80.45 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $73.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $55.60 | 2019-2023 | Rexulti |
| Pfizer INC. | $37.23 | 2022-2023 | |
| Sobi, INC | $34.54 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $34.33 | 2023 | Evusheld, Fasenra |
| Exact Sciences Corporation | $33.59 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $28.70 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.94 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Seqirus USA INC | $25.36 | 2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $14.34 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.